




















Cancer is a multi-step process that involves abrogation 
of several barriers to uncontrolled proliferation [1]. 
These barriers include checkpoints that, by activating 
inhibitory pathways, block cell division either 
reversibly (quiescence) or irreversibly (senescence, 
apoptosis). Typically, confluence and the absence of 
mitogens or nutrients induce quiescence, while cell 
ageing, inappropriate signaling or irreparable DNA 
damage lead to senescence, which is characterized by a 
large and flat cell morphology and expression of 
specific biomarkers. Cell cycle arrest requires inhibition 
of cyclin-dependent kinases (CDK), that drive division 
by both activating diverse regulators involved in 
replication and mitosis and by inactivating pRb pocket 
protein family members. While pocket proteins are 
essential for both quiescence and senescence [2], p53, 
another tumor suppressor, has been thought to play a 
key role in senescence, mainly by inducing the CDK 
inhibitor p21
Waf1,Cip1,Sdi1 (p21), which permanently 
blocks cell cycle progression [3]. On the other hand, 
although clearly involved [4], the role of p53 in 
quiescence is probably not essential, as this cell cycle 
arrest is mostly mediated by p27
Kip1 (p27), a CDK 
inhibitor whose levels are not controlled by p53 [5]. 
Consistent with this, both serum deprivation and 
confluence could efficiently induce quiescence in 
human fibroblasts expressing the HPV16-E6 viral 
oncogene, which degrades p53 [6].  
 
The straightforward role p53 in senescence has recently 
been challenged by Blagosklonny and colleagues, who 
propose that p53 is primarily a suppressor of the 






















agreement with growing evidence that p53 is involved 
in cell metabolism [4], they suggest that its another 
function would be to inhibit mTOR-dependent cell 
growth in size, thus inducing quiescence by precluding 
the onset of senescence. Consequently, senescence 
would occur in situations when the conditions for 
quiescence are not met and when p53 fails to suppress 
the mTOR pathway. This exciting but rather heretic 
hypothesis was based on initial observations showing 
that senescent phenotype requires cell growth [8, 9] and 
that, unlike ectopic p21 expression or DNA damage by 
doxorubicin, p53 induction caused quiescence instead 
of senescence in some cells [10]. By ingeniously using a 
cell line in which p21 is expressed from an inducible 
promoter and Nutlin-3A, an Mdm2 inhibitor and potent 
p53 stabilizer, they showed that over-expression or 
stabilization of p53, prevented p21-induced senescence 
and instead caused quiescence. Moreover, p53 induction 
could “convert” p21- or oxidative stress-induced 
senescence into quiescence. The principal target of p53 
in this case is the mTOR pathway, which plays a central 
role in cell size growth, as its inhibition both by nutlin 
3A and rapamycin (a classical mTOR inhibitor) favours 
quiescence over senescence [7, 11-13].  
 
These results led to a testable hypothesis predicting that 
quiescence (i.e., inactive mTOR) would also prevent 
senescence caused by genotoxic agents. Indeed, 
Leontieva and Blagosklonny now show [14] that after 
serum-deprived or rapamycin-treated normal fibroblasts 
or epithelial cells have been exposed to etoposide, its 
removal, concomitant with serum addition, enables 
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continuous presence of etoposide, serum addition 
induced senescence, presumably by activating mTOR.  
Importantly, the authors showed that neither serum 
deprivation nor rapamycin prevented p21 induction, 
while the presence of DNA damage was documented by 
the comet assay. Lastly, they showed that, serum-
deprivation prevented Nutlin 3A-induced a large, flat 
senescent morphology in some cancer cell lines.  
 
Taken at face value, these results are intriguing and 
support the initial hypothesis. However, many questions 
remained unanswered. In particular, why were 
checkpoints not activated once cells entered the cell 
cycle upon serum addition (one imagines that the DNA 
damage caused by etoposide had not been repaired)? A 
possible explanation would be that truly quiescent cells 
were not (strongly) damaged while those that were not 
entirely arrested were. It is also not clear how the cells 
got rid of high p21 levels as they resumed cycling. 
Another question concerns the role of p27 in p53-
induced reversible arrest. This is a highly relevant point, 
as mTOR inhibition blocks Akt/GSK-3-mediated p27 
phosphorylation and cytoplasmic localization and leads 
to nuclear accumulation of p27 [15]. p27-dependent 
CDK inactivation together with cyclin D1 down-
regulation could drive reversible cell cycle arrest 
together with p21 induction. Re-activation of mTOR 
(by serum addition) would revert this process enabling 
cell cycle entry, probably by degrading p27 (and p21).  
 
The most important contribution of this and previous 
work is that p53 can no longer be regarded as a bona 
fide “senescence inducer” and that its role is mainly to 
block cell division (by stimulating p21), thus permitting 
the onset of senescence program under appropriate 
conditions [7]. In agreement with this, we showed 
earlier that, while in ageing human fibroblasts HPV16-
E6-dependent p53 degradation failed to block DNA 
replication and formation of SAHFs (senescence-
associated heterochromatin foci, [16]), low p53 levels 
did not prevent cell growth and led to a flat cell 
phenotype, which is also observed in senescing p21 KO 
MEFs [6]. Thus, senescence morphology could be 
uncoupled from the cell cycle arrest, which fits with the 
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